scholarly journals Successful Treatment with Nivolumab in a Patient with Metastatic Salivary Duct Carcinoma

2021 ◽  
pp. 343-346
Author(s):  
Tsuyoshi Sato ◽  
Takahiro Maeta ◽  
Ryosuke Abe ◽  
Hiroyuki Yamada ◽  
Kazuyuki Ishida ◽  
...  
Keyword(s):  
Immunohistochemical Analysis ◽  
Salivary Duct Carcinoma ◽  
Adjuvant Chemoradiotherapy ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Hilar Lymph Node ◽  
Metastatic Lesions ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
The Right

Salivary duct carcinoma (SDC) is a rare and highly aggressive malignancy. A 58-year-old man presented with a right-sided submandibular mass and metastatic lesions in the right supraclavicular and inferior internal jugular nodes. He underwent right submandibulectomy and right neck dissection followed by adjuvant chemoradiotherapy. However, relapse occurred in the hilar lymph node and lumbar spine. Although radiotherapy was performed, a second relapse appeared in the hilar lymph nodes and sacral bone. Immunohistochemical analysis revealed negativity for programmed death ligand-1 (PD-L1) in the primary tumor specimen. The patient then received the anti-programmed death-1 (PD-1) antibody nivolumab. His metastatic lesions were completely eliminated after 48 weeks of therapy. This case reveals that anti-PD-1 antibodies are effective even against PD-L1-negative SDC.

scholarly journals Primary Salivary Duct Carcinoma Arising from the Stensen Duct

2016 ◽  
Vol 95 (9) ◽  
pp. E15-E17 ◽  
Author(s):  
Kenji Noda ◽  
Takashi Hirano ◽  
Tomoyo Okamoto ◽  
Masashi Suzuki
Keyword(s):  
Computed Tomography ◽  
Neck Dissection ◽  
Clinical Course ◽  
Additional Treatment ◽  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Histologic Diagnosis ◽  
Duct Carcinoma ◽  
The Right

This report describes a salivary duct carcinoma (SDC) arising from the extraglandular portion of the Stensen duct. The patient was a 56-year-old man who presented with a palpable, elastic, hard mass without tenderness in the right cheek. Computed tomography revealed a tumor of the extraglandular portion of the Stensen duct. Supraomohyoid right neck dissection and total right parotidectomy were performed, and the histologic diagnosis was SDC of the Stensen duct. Postoperatively, the patient received no additional treatment. Neither recurrence nor metastasis was observed during 4 years of follow-up examination. SDC of the Stensen duct is extremely rare. To our knowledge, there is no report that describes primary SDC arising from that location. We also believe this is the first report that describes the clinical course of primary SDC arising from a Stensen duct.

scholarly journals Salivary Duct Carcinoma in the External Auditory Canal Causing Ipsilateral Hearing Loss

Diagnostics ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1312
Author(s):  
Shih-Lung Chen ◽  
Chi-Ju Yeh ◽  
Kai-Chieh Chan
Keyword(s):  
Hearing Loss ◽  
External Auditory Canal ◽  
Case Reports ◽  
Benign Lesion ◽  
Immunohistochemical Analysis ◽  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Case Presentation ◽  
Subcutaneous Lesion

Background: Salivary duct carcinoma (SDC) is a rare aggressive tumor. Most tumors are not confined to the salivary ducts; rather, they invade the major and minor salivary glands. Only a few case reports on such tumors in other primary sites have appeared. Case presentation: A 40-year-old male complained of right hearing loss (a common condition), but we made an extremely rare diagnosis of an SDC in the external auditory canal (EAC). EAC cancers are frequently misdiagnosed. In our patient, the otoscope revealed a smooth, bulging subcutaneous lesion with a non-epithelial defect suggestive of a benign lesion. However, an SDC of the EAC was confirmed through pathological and immunohistochemical analysis. Conclusions: We suggest detailed evaluation of even smooth EAC subcutaneous lesions to avoid erroneous diagnoses. To the best of our knowledge, this is the first report of SDC in the EAC.

Salivary Duct Carcinoma Metastasizing to the Small Bowel

1996 ◽  
Vol 82 (5) ◽  
pp. 502-504 ◽  
Author(s):  
Božo Krušlin ◽  
Mira Ščukanec-Špoljar ◽  
Viktor Šeparović ◽  
Spomenka Manojlović ◽  
Dražn Janković ◽  
...  
Keyword(s):  
Small Bowel ◽  
Acute Appendicitis ◽  
Parotid Gland ◽  
Metastatic Tumor ◽  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
First Case ◽  
Prominent Symptom ◽  
The Right

We report a case of salivary duct carcinoma in a 47-year-old woman. The patient presented with symptoms simulating acute appendicitis. Surgery revealed metastatic tumor in the wall of the small bowel. Two months later, a tumor of the right parotid gland was resected, and histologic analysis revealed a salivary duct carcinoma. To our knowledge, this is the first case of salivary duct carcinoma metastasizing to the small bowel with manifestations of metastatic disease as the prominent symptom.

A case of salivary duct carcinoma exhibiting sarcomatoid changes in the metastatic lesions

2018 ◽  
Vol 57 (1) ◽  
pp. 39-44
Author(s):  
Kaori UETA ◽  
Nobuo HOSHI ◽  
Kimiko NAKANO ◽  
Yukiko OGURA ◽  
Miho KOBAYASHI ◽  
...  
Keyword(s):  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Metastatic Lesions

scholarly journals Long-Term Recurrence-Free Survival After Salivary Duct Carcinoma of the Parotid: A 10-Year Follow-Up Case Report

2020 ◽  
pp. 1-3
Author(s):  
Peer W. Kämmerer ◽  
D. Schneider ◽  
Peer W. Kämmerer
Keyword(s):  
Radiation Therapy ◽  
Facial Nerve ◽  
Salivary Duct Carcinoma ◽  
Adjuvant Radiation ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Parotid Region ◽  
Parotid Neoplasm ◽  
The Right

Salivary duct carcinoma (SDC) represents a very rare and aggressive parotid neoplasm. A 70-year-old male was admitted to the hospital with a swelling of the right parotid region, persisting for twelve weeks. Based on sonography and contrast-enhanced computed tomography, a suspicious lesion showing mass expansion and invasion of surrounding tissues was seen. Intraoperative biopsy brought evidence of SDC. In accordance, surgical treatment included parotidectomy with preservation of the facial nerve as well as ipsilateral neck dissection due to suspicious lymphatic nodes. Afterwards, an adjuvant radiation therapy was undertaken. At 10 years of follow-up, the patient was alive and free of recurrence with full function of the facial nerve. In conclusion, keeping in mind its poor prognosis, the rare parotid salivary duct carcinoma needs aggressive therapy consisting of a surgical as well as a radiation therapy approach.

Tumor-Infiltrating Lymphocytes and Programmed Death-Ligand 1 Expression in Salivary Duct Carcinoma

2019 ◽  
Vol 152 (Supplement_1) ◽  
pp. S40-S41
Author(s):  
Kyriakos Chatzopoulos ◽  
Andrea Collins ◽  
Joaquin Garcia
Keyword(s):  
Tumor Infiltrating Lymphocytes ◽  
Salivary Duct Carcinoma ◽  
Rank Test ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Exact Test ◽  
Log Rank Test ◽  
Programmed Death ◽  
Infiltrating Lymphocytes

Abstract Objectives Salivary duct carcinoma is a rare high-grade salivary gland tumor, sharing common features with invasive ductal carcinoma of the breast—particularly apocrine type. Increased density of tumor-infiltrating lymphocytes (TILs) is a favorable prognostic factor in many solid tumors and has been correlated with elevated expression of programmed death-ligand 1 (PD-L1), a targetable molecule. We investigated the prognostic role of TILs and PD-L1 expression in salivary duct carcinoma. Methods Clinical records and archived surgical pathology material were evaluated from 28 patients with a diagnosis of salivary duct carcinoma at Mayo Clinic Rochester (between 1961 and 2007). TILs were evaluated on hematoxylin and eosin–stained slides and reported as continuous variables. Immunohistochemistry for PD-L1 (clone 22C3) was performed on unstained slides and evaluated using the Combined Positive Score (CPS). Fisher’s exact test was used to assess frequency distribution differences. Log-rank test and Cox proportional hazards model were used to assess the impact of the variables on survival. Results Twenty-eight patients had salivary duct carcinoma (age range 35-87, mean 61), and follow-up averaged 60 months (range 6-252 months). At the end of the follow-up period, 22 patients (79%) had died of salivary duct carcinoma, while remaining patients were alive (4.14%) or had died of other causes (2.7%). For the entire follow-up period, levels of TILs of 40% or more were associated with favorable overall survival (log-rank test, P = .01) and were predictors of better survival in univariate analysis (hazard ratio: 0.18, P = .02). PD-L1 expression was not significantly different between the high and low TIL groups (Fisher’s exact test, P = .67). Survival analysis regarding PD-L1 expression did not yield statistically significant results (log-rank test, P = .74; hazard ratio: 0.87, P = .74). Conclusion High TIL levels, but not PD-L1 expression as determined using the CPS, predict better survival in patients with salivary duct carcinoma.

68-Gallium-PSMA-HBED-CC PET/CT imaging for recurrent/metastatic adenoid cystic carcinoma and salivary duct carcinoma

2019 ◽  
Author(s):  
W van Boxtel ◽  
S Lütje ◽  
AC van Engen-van Grunsven ◽  
GW Verhaegh ◽  
JA Schalken ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Ct Imaging ◽  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Adenoid Cystic ◽  
Pet Ct

Salivary Duct Carcinoma with Unusual Clinical Course of Sialolithiasis

2014 ◽  
Vol 57 (4) ◽  
pp. 251
Author(s):  
Kyung Yeon Kim ◽  
Hae Sang Park ◽  
Sung Min Chung ◽  
Han Su Kim
Keyword(s):  
Clinical Course ◽  
Salivary Duct Carcinoma ◽  
Salivary Duct ◽  
Duct Carcinoma
Sign in / Sign up

Export Citation Format

Share Document